Parabilis Medicines, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Parabilis completed a $770.5M IPO in June 2026 and ended Q2 2026 with $1.1B in cash (sufficient to fund operations into 2030). Lead program zolucatetide demonstrated 74% ORR in desmoid tumors (25 response-evaluable patients as of Feb 2026) with planned Phase 3 initiation in H1 2027. Separately, Parabilis announced a strategic collaboration with Regeneron on Antibody-Helicon Conjugates, receiving $125M ($50M upfront + $75M equity investment) with potential $2.2B in milestone payments plus tiered royalties.
Why this rating
IPO and Regeneron deal are transformative for a newly public biotech; $1.1B runway is substantial. Strong early efficacy in desmoid tumors and multi-indication pipeline support near-term catalysts, but clinical-stage risk remains high.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.